HC Wainwright Predicts Lower Earnings for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright reduced their Q1 2026 earnings estimates for shares of Delcath Systems in a note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.13. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.10 EPS and FY2028 earnings at $1.13 EPS.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%.The business had revenue of $20.73 million for the quarter, compared to analyst estimates of $20.35 million.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. BTIG Research decreased their target price on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Evercore set a $27.00 target price on shares of Delcath Systems in a report on Thursday, February 26th. Stephens cut their price target on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Delcath Systems Stock Up 7.3%

Shares of NASDAQ:DCTH opened at $9.23 on Wednesday. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $18.23. The stock’s 50 day moving average is $9.91 and its 200-day moving average is $10.16. The firm has a market capitalization of $320.74 million, a price-to-earnings ratio of 131.86 and a beta of 0.38.

Delcath Systems announced that its Board of Directors has approved a share buyback plan on Thursday, November 20th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 8.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DCTH. Simplify Asset Management Inc. raised its stake in shares of Delcath Systems by 144.9% in the third quarter. Simplify Asset Management Inc. now owns 261,126 shares of the company’s stock valued at $2,807,000 after buying an additional 154,497 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Delcath Systems in the 2nd quarter worth about $1,338,000. Geode Capital Management LLC increased its holdings in Delcath Systems by 128.1% in the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock worth $9,565,000 after acquiring an additional 394,902 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Delcath Systems in the 2nd quarter valued at about $97,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Delcath Systems during the second quarter valued at about $162,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of CHOPIN Phase 2 trial in The Lancet Oncology — The full, investigator‑initiated CHOPIN randomized Phase 2 results led by Prof. Ellen Kapiteijn were published, increasing clinical visibility and credibility for Delcath’s liver‑directed chemotherapy platform; this type of high‑profile peer‑reviewed publication can support investor confidence and future regulatory/commercial discussions. Article Title Business Wire Release
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $30 price target — the firm continues to show long‑term conviction even as it revises near‑term numbers, which may temper negative reactions relative to a full downgrade.
• Neutral Sentiment: Long‑range forecasts mixed — HC Wainwright published multi‑year model estimates (including a new FY2030 EPS projection), showing a path to profitability further out; these farther‑out estimates are informative but less likely to move the stock as much as near‑term revisions.
• Neutral Sentiment: Short interest report shows no meaningful data change — the reported short interest figures appear to be zero/erroneous and do not indicate increased short pressure at this time.
• Negative Sentiment: Multiple downward EPS revisions from HC Wainwright — the analyst cut Q1–Q4 2026 and FY2026 estimates significantly (examples: Q1 from $0.13 to ($0.01), Q2 from $0.08 to ($0.15), Q3 from $0.10 to ($0.42), and FY2026 from $0.58 to ($0.86)), and lowered FY2027‑FY2029/FY2028/FY2029 forecasts as well. Those near‑term cuts increase uncertainty about upcoming quarters and could limit upside despite the trial publication.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.